Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers

Abstract

LCB01-0371 is a novel oxazolidinone with broad-spectrum activity against Gram-positive pathogens in both in vitro studies and animal infection models. The objectives of this study were to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics following single ascending doses. Single oral doses of 600 mg linezolid, a placebo, or LCB01-0371 of between 50 mg and 3,200 mg were tested in 69 healthy male subjects. Blood and urine were sampled, LCB01-0371 concentrations were measured, and the serum inhibitory and bactericidal titers of LCB01-0371 and linezolid were determined. LCB01-0371 was well tolerated up to 2,400 mg. The most common drug-related clinical and laboratory adverse events were nausea with or without vomiting, decreased neutrophil counts, and increased total bilirubin levels. The frequency of adverse events and drug-related adverse events was similar among the treatment groups. The systemic exposure was approximately dose proportional over the range of 50 mg to 800 mg, which includes the anticipated clinical dose. The mean clearance, renal clearance, and volume of distribution were significantly decreased at higher doses (above 800 mg). LCB01-0371 exhibited early bacteriostatic activity against all tested strains except for Streptococcus pneumoniae strains, and the potency of LCB01-0371 at 800 mg was similar to that of linezolid at the therapeutic dose (600 mg). However, LCB01-0371 had less bactericidal activity than linezolid. Taken together, LCB01-0371 was well tolerated, exhibited approximate dose proportionality within the anticipated clinically relevant dose range, and showed bacteriostatic and bactericidal activity comparable to that of linezolid. These results support the further clinical development of LCB01-0371. (This study has been registered at ClinicalTrials.gov under registration no. NCT01554995.).

Keywords: LCB01-0371; pharmacodynamics; pharmacokinetics; safety; tolerability.

Copyright © 2018 American Society for Microbiology.

Figures

FIG 1

Chemical structure of LCB01-0371 ((R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazine-4(1H)-yl)penyl)-5-(hydroxymethyl) oxazolidin-2-one).

FIG 2

Mean plasma concentration-time profiles of LCB01-0371 following a single oral dose of 50, 100, 200, 400, 800, 1,600, 2,400, or 3,200 mg.

FIG 3

Mean and 90% CI of Cmax (A), AUClast (B), and AUCinf (C) versus dose following a single oral dose of 50, 100, 200, 400, 800, 1,600, 2,400, or 3,200 mg. The points indicate individual values.